Abbott sues ImClone

In a complaint filed 5 Feb in D. Mass. (Boston), Abbott asserted ImClone makes Erbitux by "willfully and knowingly" using Abbott's patented method for creating antibodies.

A distinct lawsuit is pending in Boston over a related patent. Repligen Corp. and the Massachusetts Institute of Technology sued ImClone for infringement in 2004. Repligen has an exclusive license to MIT's patent for a cell line it claims was used to develop Erbitux. [IPBiz: university as plaintiff.]

There was also a case on inventorship.